Inventiva (NASDAQ:IVA) Stock Price Down 5.5% After Earnings Miss

Key Points

• Inventiva shares fell 5.5% after the company reported a quarterly loss of $0.14 per share and $0.75 million in revenue, underscoring weak near-term earnings performance.
• The company ended the first half with approximately €166.1 million in cash and expects its cash runway to extend through the second quarter of 2027, easing immediate financing concerns.
• Investor attention is focused on the upcoming Phase 3 NATiV3 readout for lanifibranor in MASH. Despite the earnings miss, analysts maintain a consensus “Buy” rating and a $15.75 price target.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report)'s share price traded down 5.5% on Tuesday following a weaker than expected earnings announcement. The company traded as low as $3.33 and last traded at $3.3350. 2,176,702 shares changed hands during trading, an increase of 180% from the average daily volume of 778,476 shares. The stock had previously closed at $3.53.

The company reported ($0.14) EPS for the quarter. The business had revenue of $0.75 million for the quarter.

Inventiva News Summary

Here are the key news stories impacting Inventiva this week:

• Positive Sentiment: Inventiva reported cash and cash equivalents of approximately €166.1 million at the end of the first half, strengthening its balance sheet ahead of the Phase 3 NATiV3 results. Management maintained its cash runway through the end of the second quarter of 2027, reducing near-term financing concerns. Inventiva strengthens cash position before NATiV3 results Inventiva cash runway remains unchanged
• Positive Sentiment: First-half net loss narrowed substantially from the prior-year period, improving the company’s cost and cash-burn profile. Investors are also focused on the expected NATiV3 Phase 3 readout for lanifibranor in MASH, which is anticipated this quarter and represents the company’s most important near-term catalyst. Inventiva first-half loss plunges and MASH readout approaches
• Positive Sentiment: Several market opinions remain favorable, helping reinforce optimism around Inventiva’s clinical pipeline and the potential value of a successful NATiV3 outcome. Inventiva receives several positive opinions
• Neutral Sentiment: The company’s first-half update and earnings presentation emphasize that the investment case remains centered on clinical execution rather than current product revenue. Inventiva first-half financial results and corporate update
• Negative Sentiment: The latest quarterly release reported a loss of $0.28 per share versus the $0.20 expected loss, while revenue of $0.02 million was far below the $2.88 million consensus estimate. The earnings shortfall may limit gains until investors receive clearer evidence from the NATiV3 trial. Inventiva quarterly earnings report

Analysts Set New Price Targets

IVA has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Inventiva in a research report on Friday, July 17th. Cantor Fitzgerald assumed coverage on shares of Inventiva in a research note on Friday, July 17th. They set an "overweight" rating for the company. Piper Sandler reaffirmed an "overweight" rating on shares of Inventiva in a report on Wednesday, September 16th. Finally, Guggenheim upped their price target on shares of Inventiva from $11.00 to $14.00 and gave the company a "buy" rating in a research note on Tuesday, September 15th. Three analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $15.75.

Institutional Trading of Inventiva

Several hedge funds and other institutional investors have recently bought and sold shares of IVA. NEXTBio Capital Management LP bought a new position in shares of Inventiva during the fourth quarter worth approximately $6,039,000. Propel Bio Management LLC bought a new stake in shares of Inventiva in the fourth quarter valued at approximately $4,650,000. Eventide Asset Management LLC acquired a new stake in Inventiva during the fourth quarter worth approximately $1,155,000. Seven Fleet Capital Management LP bought a new position in Inventiva during the 1st quarter worth $1,111,000. Finally, Persistent Asset Partners Ltd bought a new position in Inventiva during the 4th quarter worth $603,000. Institutional investors and hedge funds own 19.06% of the company's stock.

Inventiva Stock Down 5.5%

The company has a fifty day simple moving average of $4.41 and a two-hundred day simple moving average of $4.73.

Inventiva Company Profile

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company develops small-molecule therapies for metabolic, liver and autoimmune diseases, with a focus on conditions that have limited treatment options.

Inventiva's lead product candidate is lanifibranor, an oral pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). The investigational therapy is intended to address liver inflammation and fibrosis associated with the disease and is being evaluated in late-stage clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.